Attending: Expert: User: Stage 1: History & Longitudinal Presentation (Timestamp: 8 Months Prior to Admission)
A 91-year-old male retired military veteran (residing in Delhi NCR, 30-pack-year smoking history, past history of COPD, CAD S/P stenting, paroxysmal atrial fibrillation, BPH) presents with an 8-month history of progressive exertional dyspnea, 15.9 kg weight loss, chronic sinus congestion, rhinorrhea, anosmia, and severe blood eosinophilia.
HPI:
- 8 Months Ago: Onset of exertional dyspnea, sinus congestion, and anosmia. Absolute Eosinophil Count (AEC) elevated at 1,280/µL.
- 6 Months Ago: Hospitalized with dyspnea and left upper lobe pulmonary opacity. AEC 1,370/µL. Treated with oral steroids and antibiotics with temporary relief.
- 2 Months Ago: Readmitted with respiratory failure during an Influenza A infection; chest X-ray showed fluctuating bibasilar opacities and AEC surged to 2,090/µL.
Hello, Chief Resident here.
Key Findings:
A 91-year-old male presenting with chronic rhinosinusitis, anosmia, significant weight loss (15.9 kg), progressive dyspnea, steroid-responsive fluctuating pulmonary opacities, and escalating peripheral hypereosinophilia (AEC peaking at 2,090/µL).
Differential Diagnoses:
1. Eosinophilic Granulomatosis with Polyangiitis (EGPA): 55% — Strongest fit given triphasic presentation (prodromal rhinosinusitis/anosmia, eosinophilia, and pulmonary/systemic vasculitic involvement).
2. Allergic Bronchopulmonary Aspergillosis (ABPA): 20% — Explains underlying obstructive airway disease, severe eosinophilia, sinus involvement, and migratory infiltrates.
3. Chronic Eosinophilic Pneumonia (CEP): 15% — Matches severe constitutional symptoms, profound peripheral eosinophilia, and steroid-responsive migratory pulmonary opacities.
4. Hypereosinophilic Syndrome (HES) / Paraneoplastic Eosinophilia: 10% — Persistent AEC >1,500/µL with organ involvement; given age and 30-pack-year smoking history, underlying occult malignancy must be considered.
Recommended Prioritized Tests:
1. ANCA Panel (p-ANCA/MPO and c-ANCA/PR3).
2. Serum Total IgE and Aspergillus-specific IgE/IgG.
3. High-Resolution CT (HRCT) Chest and Paranasal Sinuses to evaluate tissue involvement and bronchiectasis.
4. Stool Ova/Parasites & Strongyloides Serology to exclude hyperinfection prior to escalating systemic corticosteroids.
5. Peripheral Blood Smear and bone marrow/genetic screen (FIP1L1-PDGFRA) if myeloproliferative HES is suspected.
Hello Attending Consultant here
Critique: Solid prioritization of EGPA, but underweights malignancy/paraneoplastic drivers given age, smoking, and cachexia. ABPA less likely sans asthma/central bronchiectasis history. Omit BM initially; escalate only if FIP1L1 negative and AEC persists. Add cardiac/renal screens early—EGPA mortality hinges on them.
Top 3 DDx:
1. EGPA (ANCA-neg variant common in elderly)
2. Paraneoplastic hypereosinophilia (occult lung ca/lymphoma)
3. Idiopathic HES vs CEP overlap
5 Specific Points:
1. Order troponin/BNP + echo for eosinophilic myocarditis.
2. UA + spot PCR for glomerulonephritis.
3. CT chest/abdomen/pelvis for malignancy staging.
4. Serum tryptase + B12 to screen myeloproliferative HES.
5. Hold high-dose steroids pending Strongyloides result; use empiric ivermectin if delay.
6. Quantiferon + HIV to exclude mimics.
7. ENT scope + biopsy if sinus disease progresses.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Eosinophilic Granulomatosis with Polyangiitis (EGPA). The triphasic arc—prodromal sinonasal disease (congestion, anosmia), escalating blood eosinophilia, then steroid-responsive migratory pulmonary opacities—is the classic EGPA trajectory. His "COPD" may partly represent undiagnosed late-onset asthma, a common EGPA antecedent.
Differentials:
- ABPA: Fits eosinophilia and fleeting infiltrates, but no asthma/central bronchiectasis, and doesn't explain weight loss or systemic features.
- Chronic eosinophilic pneumonia: Fits opacities and eosinophilia, but not the prominent sinonasal disease.
- Paraneoplastic/occult malignancy: Age, smoking, and 15.9 kg loss demand exclusion; eosinophilia can be tumor-driven.
- Idiopathic HES: Diagnosis of exclusion; requires AEC >1,500 with organ damage and no secondary cause.
Key Pivot: Anosmia + chronic sinusitis + hypereosinophilia + migratory infiltrates shifts this from "refractory COPD/pneumonia" to systemic eosinophilic vasculitis.
Next Move: ANCA (MPO), HRCT chest/sinuses, echocardiogram/troponin (cardiac involvement drives mortality), urinalysis, Strongyloides serology before further steroids, and age-appropriate malignancy screen; tissue biopsy (sinus/skin/nerve) if diagnosis remains uncertain.
Teaching Pearl: In an elderly "COPD" patient with new eosinophilia and anosmia, think EGPA—asthma is often mislabeled as COPD for years before vasculitis declares itself.
Stage 2: Physical & Laboratory Evaluation (Timestamp: Admission / Day 1)
Physical Exam: T 35.6°C, HR 71 bpm (irregularly irregular AFib), BP 98/54 mmHg, RR 20/min, SpO2 70% on room air post-ambulation (95% at rest). Severe diffuse pulmonary wheezing, no crackles, no rash, no organomegaly.
Initial Laboratory Evaluation:
- Profound Hypereosinophilia: Total WBC 37,780/µL, Hemoglobin 12.8 g/dL, Platelets 248,000/µL. Absolute Eosinophil Count (AEC): 27,390/µL (72.5% eosinophils). Smear shows mature, reactive bilobed vacuolated eosinophils without blasts.
- Cardiac Biomarkers: High-sensitivity Troponin T elevated at 56 ng/L, NT-proBNP 4,300 pg/mL (myocardial eosinophilic involvement).
- Immunoglobulins & Inflammatory Panel: Serum IgG 3,099 mg/dL, IgE 266 IU/mL, Aspergillus fumigatus specific IgE 2.99 kU/L. ESR 49 mm/hr, CRP 28.0 mg/L.
- Normal Myeloproliferative Markers: Serum B12 912 pg/mL, Serum Tryptase 6.3 ng/mL (normal, arguing against FIP1L1-PDGFRA fusion). Normal liver and renal function.
Hello, Chief Resident here.
Updated Key Findings:
Dramatic surge in peripheral hypereosinophilia to AEC 27,390/µL (72.5% vacuolated eosinophils), severe exertional hypoxia, and direct evidence of acute eosinophilic myocardial involvement (hs-Troponin T 56 ng/L, NT-proBNP 4,300 pg/mL).
Probability-Based Diagnoses:
1. EGPA with Cardiac Involvement: 60% — Fits the sinonasal prodrome, severe obstructive airway disease, explosive hypereosinophilia, and life-threatening eosinophilic myocarditis.
2. Idiopathic / Reactive Hypereosinophilic Syndrome (HES): 20% — Massive AEC >1,500/µL with multi-organ toxicity (cardiac/pulmonary); normal tryptase/B12 makes primary myeloproliferative variants less likely, though still possible.
3. Paraneoplastic Hypereosinophilia: 15% — Extreme AEC spike combined with 15.9 kg loss and smoking history demands exclusion of eosinophil-CSF-secreting occult solid tumor or T-cell lymphoma.
4. ABPA: 5% — Low-positive Aspergillus IgE noted, but AEC >27,000/µL and acute myocarditis extend far beyond typical ABPA.
Prioritized Management & Diagnostic Steps:
1. Urgent Echocardiogram to assess ventricular function, endomyocardial thickening, or intracardiac thrombi.
2. Pulse IV Methylprednisolone (with empiric ivermectin coverage) given life-threatening eosinophilic myocarditis.
3. ANCA (MPO/PR3) and FIP1L1-PDGFRA molecular testing.
4. CT Chest/Abdomen/Pelvis to evaluate pulmonary infiltrates and rule out underlying malignancy.
Hello Attending Consultant here
Critique: Appropriately escalates for myocarditis and deprioritizes ABPA. Over-relies on empiric pulse steroids without confirming Strongyloides clearance or securing airway/O2 first. FIP1L1 testing correct but pair with flow cytometry; CT alone insufficient—add PET if mass found. Delay non-urgent ANCA results should not halt therapy.
Top 3 DDx:
1. EGPA (cardiac-predominant, ANCA-neg)
2. Idiopathic HES with endomyocardial damage
3. Paraneoplastic eosinophilia (occult NSCLC/lymphoma)
6 Specific Points:
1. Immediate high-flow O2/NIV; serial ABGs for impending failure.
2. Empiric ivermectin + albendazole now; steroids only after first dose.
3. Urgent TTE + cardiac MRI if stable (thrombus/fibrosis risk).
4. Peripheral flow cytometry + T-cell receptor gene rearrangement.
5. Bronchoscopy + BAL eosinophil % once oxygenated.
6. Hold anticoagulation decision pending echo (AFib + thrombus risk).
Hello, Expert Clinician here.
Best Unifying Diagnosis: EGPA with eosinophilic myocarditis. The AEC explosion to 27,390/µL with troponin elevation and BNP 4,300 signals cardiac involvement—the leading cause of EGPA mortality. Normal tryptase/B12 argues against myeloproliferative HES; modest IgE/Aspergillus titers make ABPA untenable at this eosinophil magnitude.
Differentials:
- Idiopathic HES: Fits AEC >1,500 with cardiac damage, but the 8-month sinonasal prodrome with anosmia strongly favors EGPA.
- Paraneoplastic eosinophilia: Must exclude given smoking, weight loss, and extreme AEC; solid tumors and T-cell lymphomas secrete eosinophilopoietic cytokines.
- Lymphocytic-variant HES: Check flow cytometry for aberrant T-cell clones.
Key Pivot: Troponin elevation transforms this from diagnostic workup to therapeutic emergency—cardiac involvement mandates immediate immunosuppression.
Next Move: Pulse IV methylprednisolone now (cover with empiric ivermectin given steroid history), urgent echocardiogram ± cardiac MRI, flow cytometry/TCR rearrangement, CT chest/abdomen/pelvis for malignancy, and ANCA/FIP1L1 testing. Biopsy (skin, nerve, or endomyocardial) if diagnosis remains uncertain after stabilization.
Teaching Pearl: In hypereosinophilia, troponin is the alarm bell—eosinophilic myocarditis kills silently and demands steroids before the workup is complete.
Stage 3: Chest CT Imaging & Diagnostic Bronchoscopy (Timestamp: Hospital Days 1-2)
Diagnostic Workup:
- High-Resolution Chest/Abdomen CT:
- Lung Windows: Diffuse bronchial-wall thickening, mucus plugging, right lower lobe tree-in-bud opacities, and bilateral subsegmental atelectasis with small bilateral pleural effusions.
- Soft Tissue & Abdominal Windows: Subcarinal mediastinal lymphadenopathy (1.8 cm), hydroureteronephrosis of the left kidney secondary to bladder outlet obstruction/prostatic enlargement.
- Cardiopulmonary Function: ECG confirmed atrial fibrillation with rapid ventricular response and intraventricular conduction delay without acute ST shifts. Echo showed normal LVEF without overt valvular destruction.
Hello, Chief Resident here.
Key Findings:
CT reveals severe eosinophilic airway involvement (bronchial thickening, mucus plugging, tree-in-bud opacities), bilateral pleural effusions, subcarinal lymphadenopathy (1.8 cm), and acute left hydroureteronephrosis secondary to urinary retention/BPH.
Probability-Based Diagnoses:
1. EGPA: 65% — Airway disease, tree-in-bud opacities, effusions, sinonasal/anosmia prodrome, explosive AEC, and cardiac elevation strongly point to systemic vasculitis.
2. Idiopathic Hypereosinophilic Syndrome (HES): 20% — Extensive multi-organ organ involvement driven by extreme hypereosinophilia (>27,000/µL).
3. Paraneoplastic Eosinophilia / Lymphoma: 10% — Mediastinal lymphadenopathy, 15.9 kg weight loss, and 30-pack-year smoking history demand exclusion of underlying malignancy.
4. ABPA: 5% — Mucus plugging and bronchial thickening fit, but cannot account for systemic features or cardiac biomarkers.
Prioritized Next Steps:
1. Urgent Urinary Catheterization to relieve left hydronephrosis and prevent renal failure.
2. Bronchoscopy with BAL (cell differential, fungal/microbial stains, cytology) ± EBUS-TBNA of subcarinal lymph node.
3. Initiate High-Dose Corticosteroids (with strongyloides cover/ivermectin) for severe pulmonary-cardiac involvement.
4. Cardiac MRI to detect early endomyocardial fibrosis or patchy eosinophilic myocarditis missed on echocardiogram.
Hello Attending Consultant here
Critique: Solid airway focus and hydronephrosis relief; correctly de-emphasizes ABPA. Overcalls EGPA probability without ANCA/tissue yet—LAD and tree-in-bud broaden infection/malignancy. Echo normal EF does not exclude myocarditis; MRI essential. Steroids still premature sans confirmed Strongyloides Rx and BAL data.
Top 3 DDx:
1. EGPA (ANCA-neg, airway-cardiac)
2. Idiopathic HES (lymphocytic variant)
3. Paraneoplastic (NSCLC/lymphoma via LAD)
6 Specific Points:
1. Foley now; urology for TURP eval post-stabilization.
2. BAL differential + bacterial/fungal/AFB/PCP PCR before steroids.
3. EBUS-TBNA of 1.8 cm node for cytology/flow.
4. Cardiac MRI (T2/late gadolinium) for occult myocarditis.
5. Empiric ivermectin ×2 days; then methylpred 1 mg/kg.
6. Repeat AEC q12h; add mepolizumab if steroid-refractory.
Hello, Expert Clinician here.
Best Unifying Diagnosis: EGPA with airway-predominant disease and early cardiac involvement. Bronchial wall thickening, mucus plugging, and tree-in-bud opacities reflect eosinophilic airway inflammation; pleural effusions and troponin elevation signal systemic vasculitis. Normal LVEF does not exclude myocarditis—cardiac MRI is essential.
Differentials:
- Idiopathic HES: Fits extreme AEC and multi-organ involvement, but sinonasal prodrome and airway-centric CT favor EGPA.
- Paraneoplastic eosinophilia: Subcarinal lymphadenopathy (1.8 cm) plus smoking/weight loss mandate EBUS-TBNA to exclude occult malignancy.
- ABPA: Mucus plugging fits, but cannot explain effusions, cardiac biomarkers, or AEC >27,000/µL.
Key Pivot: Tree-in-bud opacities plus lymphadenopathy broaden the differential—infection (TB, fungal) and malignancy must be excluded via bronchoscopy before committing to prolonged immunosuppression.
Next Move: Foley catheter for hydronephrosis, bronchoscopy with BAL (differential, cultures, cytology) and EBUS-TBNA of the subcarinal node, cardiac MRI, then pulse steroids with ivermectin cover once infection is reasonably excluded.
Teaching Pearl: In hypereosinophilia, tree-in-bud opacities are not always infection—eosinophilic airway plugging can mimic endobronchial spread, but tissue confirmation prevents catastrophic misdiagnosis.
Stage 4: Serologic ANCA Panel, Flow Cytometry & Molecular Genomics (Timestamp: Hospital Days 2-4)
Serologies & Molecular Genomics:
- ANCA Serology & Immunoassay:
- c-ANCA Positive by indirect immunofluorescence.
- PR3-ANCA (Proteinase 3) ELISA: >100 U/mL (Strongly Positive, ref <20 U/mL); MPO-ANCA negative.
- Flow Cytometry & Somatic Gene Fusion Panel:
- Normal B-cell kappa/lambda light chain ratio; intact T-cell TRBC1/TRBC2 expression without CD3-CD4+ clonal T-cell populations.
- RT-PCR/NGS negative for FIP1L1-PDGFRA, BCR-ABL1, or FGFR1 gene fusions (excluding myeloproliferative hypereosinophilic syndrome).
- Next-Generation Sequencing detected Clonal Hematopoiesis of Indeterminate Potential (CHIP) mutations (ASXL1 VAF 32.8%, TET2 VAF 17.4%).
- Pathology Unifying Diagnosis: Eosinophilic Granulomatosis with Polyangiitis (EGPA / Churg-Strauss Syndrome) with PR3-ANCA positivity and CHIP.
Hello, Chief Resident here.
Updated Key Findings:
Strongly positive PR3-ANCA (>100 U/mL) and c-ANCA, negative myeloproliferative gene fusions (FIP1L1-PDGFRA), normal T-cell flow cytometry, and co-existing Clonal Hematopoiesis of Indeterminate Potential (ASXL1, TET2).
Final Diagnoses & Probabilities:
1. Eosinophilic Granulomatosis with Polyangiitis (EGPA) - PR3-ANCA Positive Variant: 90% — Confirmed by classic clinical presentation (sinonasal disease, late-onset obstructive airway disease, migratory pulmonary opacities, hypereosinophilia, myocarditis) and strongly positive PR3-ANCA. (Note: While MPO is classic, PR3-ANCA occurs in ~10-15% of EGPA cases).
2. Idiopathic Hypereosinophilic Syndrome (HES) with CHIP: 8% — Excluded as primary driver given specific PR3-ANCA positivity, though CHIP mutational burden (ASXL1, TET2) reflects age-related clonal hematopoiesis.
3. Paraneoplastic Eosinophilia: 2% — Less likely given positive ANCA and negative initial malignant flow, though CHIP mandates ongoing surveillance.
Management & Next Steps:
1. Induction Therapy: Initiate High-dose IV Methylprednisolone (0.5–1 g/day for 3 days) followed by oral prednisone (1 mg/kg/day).
2. Targeted Immunosuppression: Add Cyclophosphamide or Rituximab given life-threatening organ involvement (eosinophilic myocarditis / PR3-ANCA variant).
3. Eosinophil-Targeted Therapy: Consider Mepolizumab (anti-IL-5) for maintenance/refractory disease.
4. Cardioprotection & Secondary Prevention: Continue heart failure management and provide Pneumocystis jirovecii (TMP-SMX) and Strongyloides prophylaxis.
Hello Attending Consultant here
Critique: Correctly locks EGPA but overstates certainty—PR3-ANCA EGPA is atypical (5-10%); consider GPA-EGPA overlap given c-ANCA/PR3 titer. CHIP (ASXL1/TET2) is age-expected, not driver. Induction plan solid, yet rituximab preferred over CYC in elderly; mepolizumab timing premature pre-remission. No biopsy confirmation yet.
Top 3 DDx:
1. PR3+ EGPA (cardiac-airway)
2. GPA-EGPA overlap syndrome
3. ANCA+ HES mimic (CHIP-related)
6 Specific Points:
1. Prefer RTX 375 mg/m² weekly ×4 over CYC (lower infection risk at 91 yo).
2. Pulse MP 1 g ×3 d then prednisone 1 mg/kg + PJP/TMP-SMX ppx.
3. Cardiac MRI + serial troponin/BNP to quantify myocarditis burden.
4. ENT/sinus biopsy if feasible for histologic confirmation.
5. Hold mepolizumab until steroid taper; monitor AEC q48h.
6. Urology TURP planning + anticoagulation restart post-echo clearance.
7. CHIP surveillance only; no hematology referral needed now.
Hello, Expert Clinician here.
Best Unifying Diagnosis: PR3-ANCA positive EGPA with cardiac involvement. The clinical triphasic arc (sinonasal prodrome → hypereosinophilia → systemic vasculitis) plus strongly positive PR3-ANCA confirms EGPA, though PR3 positivity (vs. typical MPO) suggests a GPA-overlap phenotype with potentially higher relapse risk. CHIP mutations (ASXL1, TET2) are age-appropriate incidental findings, not disease drivers.
Differentials:
- GPA-EGPA overlap: PR3 dominance raises this; monitor for renal involvement or granulomatous destruction.
- ANCA-associated HES mimic: Excluded by negative FIP1L1-PDGFRA and normal flow cytometry.
- Paraneoplastic: Effectively excluded by ANCA specificity and negative malignancy workup.
Key Pivot: PR3-ANCA positivity transforms this from "eosinophilic syndrome" to confirmed systemic vasculitis, mandating aggressive induction immunosuppression despite advanced age.
Next Move: Pulse methylprednisolone (1 g × 3 days) then prednisone 1 mg/kg, plus rituximab (preferred over cyclophosphamide in elderly for infection risk). Cardiac MRI to quantify myocarditis, PJP prophylaxis, and hold mepolizumab until steroid taper. Biopsy (sinus or endomyocardial) if feasible for histologic confirmation.
Teaching Pearl: PR3-ANCA occurs in ~10% of EGPA and portends a GPA-like phenotype—expect higher relapse rates and consider rituximab over cyclophosphamide for induction in elderly patients.
Stage 5: Targeted Anti-IL-5 Monoclonal Antibody Therapy & Complete Remission (Timestamp: Follow-up & Discharge)
Management & Outcome:
- Targeted Management Plan:
- Induction: High-dose oral Prednisone with a 6-month structured taper.
- Targeted Biologic Therapy: Benralizumab (anti-IL-5 receptor alpha monoclonal antibody) administered subcutaneously.
- Clinical Outcome:
- Rapid decline in Absolute Eosinophil Count from 27,390/µL to 0/µL at 6 weeks, maintained at 20–30/µL.
- PR3-ANCA titers became undetectable at 3 months; complete normalization of ESR, CRP, and chest radiograph opacities with successful steroid weaning.
Hello, Chief Resident here.
Updated Key Findings:
Complete clinical, radiologic, and serologic remission of PR3-ANCA positive EGPA following targeted therapy with prednisone and Benralizumab (anti-IL-5Rα). AEC normalized from 27,390/µL to 0/µL, PR3-ANCA titers became undetectable, inflammatory markers normalized, and pulmonary opacities resolved.
Probability-Based Diagnoses:
1. PR3-ANCA Positive EGPA (Complete Remission): 98% — Confirmed by classic multi-organ clinical features, PR3-ANCA positivity, and complete response to targeted anti-IL-5 receptor blockade.
2. Incidental Clonal Hematopoiesis of Indeterminate Potential (CHIP): 2% — Pre-existing ASXL1/TET2 mutations were non-contributory to the acute presentation but remain an incidental finding.
Recommended Management & Follow-up Plan:
1. Maintenance Therapy: Continue Benralizumab maintenance injections and complete the structured oral prednisone taper.
2. Relapse Surveillance: Track serial AEC, PR3-ANCA titers, and inflammatory markers (ESR/CRP) every 3–6 months.
3. Cardiovascular Monitoring: Repeat echocardiogram and serial cardiac biomarkers (troponin, NT-proBNP) at 6 months to confirm absence of subclinical myocardial inflammation.
4. Prophylaxis: Maintain Pneumocystis jirovecii prophylaxis (TMP-SMX) until prednisone is fully tapered below 10 mg/day.
5. Hematology Surveillance: Annual CBC and peripheral smear to monitor CHIP mutational status.
Hello Attending Consultant here
Critique: Excellent outcome tracking and AEC/ANCA surveillance. Over-relies on Benralizumab monotherapy post-induction—PR3+ EGPA carries higher relapse risk; dual RTX bridge preferred initially. CHIP monitoring excessive (no MDS progression signal). Cardiac re-eval timing laggy given prior myocarditis.
Top 3 DDx:
1. PR3+ EGPA in complete remission (anti-IL-5R response)
2. GPA-EGPA overlap (PR3-driven, relapse-prone)
3. Residual CHIP-associated eosinophilic clone (low probability)
6 Specific Points:
1. Bridge with RTX 1 g ×2 if any ANCA re-rise during taper.
2. Cardiac MRI + troponin/BNP at 3 mo (not 6) for fibrosis.
3. Stop TMP-SMX at prednisone <5 mg; add bone density scan.
4. Benralizumab q8wk maintenance; AEC/PR3 q3mo ×2 yr.
5. No routine CHIP NGS; CBC only if cytopenias emerge.
6. ENT re-scope + PFTs at 6 mo for subclinical airway activity.
7. Restart DOAC for AFib once stable off high-dose steroids.
Hello, Expert Clinician here.
Best Unifying Diagnosis: PR3-ANCA positive EGPA in complete remission following benralizumab plus prednisone. The dramatic AEC collapse (27,390 → 0/µL) with undetectable PR3 titers and radiographic resolution confirms IL-5 pathway dependence and validates the diagnosis. However, PR3-positive EGPA carries higher relapse risk than MPO-positive disease—vigilant surveillance is essential.
Differentials:
- GPA-EGPA overlap: PR3 dominance suggests relapse-prone phenotype; monitor for granulomatous or renal manifestations during taper.
- Residual clonal eosinophilia: CHIP mutations are incidental; no myeloproliferative driver identified.
- Steroid-dependent remission: Risk of relapse during taper remains; benralizumab provides steroid-sparing coverage.
Key Pivot: Benralizumab's efficacy here demonstrates that eosinophil depletion alone can suppress even ANCA-positive vasculitis, challenging the paradigm that ANCA titers mandate B-cell depletion for all EGPA.
Next Move: Continue benralizumab maintenance, complete prednisone taper, serial AEC/PR3/ESR/CRP every 3 months for 2 years, cardiac MRI at 3 months to exclude residual fibrosis, and PFTs/ENT re-evaluation at 6 months. Consider rituximab bridge if PR3 re-emerges during taper.
Teaching Pearl: Anti-IL-5R biologics can induce deep remission even in PR3-positive EGPA—but PR3 positivity predicts relapse, so taper steroids cautiously and never stop surveillance.